SRTANasdaqServices-Health ServicesFiscal year ends December 31

Strata Critical Medical, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$4.54+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $391.41M
P/E (TTM): 8.9
Dividend yield: –

Strata Critical Medical, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2021 2021-09-30	FY 2020 2020-09-30	FY 2019 2019-09-30
Revenue	197	147	225	51	23	31
Cost of Revenue	156	117	183	40	21	26
Gross Profit	41	30	42	11	2.33	4.70
Selling, General & Admin	61	51	106	33	12	15
Selling & Marketing	–	7.95	10	2.79	2.53	5.01
General & Administrative	–	82	95	30	9.29	10
Advertising Expenses	–	2.71	4.06	1.89	0.88	1.78
Operating Expenses	63	52	-33	-25	–	–
Total Costs & Expenses	–	283	293	75	34	43
Operating Income	-22	-23	-68	-24	-10	-12
Other Non-Operating Income	2.29	6.36	11	-20	0.20	0.70
Merger & Restructuring Charges	–	1.44	–	–	–	–
Gain (Loss) on Investments	-5.20	0	0.01	0	–	–
Gain (Loss) on Sale of Assets	-2.07	0	-0.05	0	0	-0.03
Pretax Income	-20	-16	-58	-44	-10	-11
Income Tax Expense	0	0	-1.47	-3.64	0	0
Income from Continuing Operations	-20	-16	–	–	–	–
Income from Discontinued Operations	61	-11	–	–	–	–
Net Income	41	-27	-56	-40	-10	-11
EPS (Basic)(per share)	0.50	-0.35	-0.76	-0.93	-0.40	-0.43
EPS (Diluted)(per share)	0.50	-0.35	-0.76	-0.93	-0.40	-0.43
Shares Outstanding (Basic, Weighted)(shares)	82	77	74	43	25	25
Shares Outstanding (Diluted, Weighted)(shares)	82	77	74	43	25	25
EBITDA	-14	-17	-61	-23	-9.83	-11
Net Interest Income	–	7.21	8.44	0.46	0.20	0.70

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 20.6%
Operating margin: -8.0%
Net margin: 15.7%
Return on equity, FY2025: 16.5%

Financial strength

Current ratio: 2.64
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 35.6%

Valuation

P/E ratio: 8.9
Price to sales: 1.53
Price to book: 1.40
Dividend yield: –